TC BioPharm is a clinical-stage biopharmaceutical company based in Scotland developing cell therapies for cancer using gamma delta T (GD-T) cells — a type of white blood cell that naturally targets and destroys cancer cells by recognizing stress signals on diseased cell surfaces. TC BioPharm harvests GD-T cells from healthy donors, expands them in its in-house manufacturing facility, and infuses them into patients to attack malignant tissue. The company has two main programs: OmnImmune, an unmodified allogeneic GD-T cell therapy targeting acute myeloid leukemia (AML), which is currently in a Phase 2b/3 trial called ACHIEVE; and a pre-clinical CAR-modified GD-T cell program targeting solid tumors. TC BioPharm is pre-revenue and funds operations through grants, equity raises, and collaboration agreements. The intended commercial model is selling off-the-shelf cell therapy products to hospitals and oncology centers. TC BioPharm's allogeneic approach — manufacturing from donor cell banks rather than individual patients — allows batch production and frozen storage, which TC BioPharm argues results in lower costs and simpler logistics compared to autologous CAR-T therapies. TC BioPharm also manufactures its products in-house, which it argues reduces costs and speeds development by eliminating third-party manufacturers and research organizations. The company has also developed a proprietary cryopreservation process enabling global shipping without shelf-life constraints.